Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
LSTA · NASDAQ · Pharmaceutical Preparations
Lisata Therapeutics (LSTA) · oqro.io/stocks/LSTA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Lisata Therapeutics was filed in the last 90 days. The latest on record was on Dec 8, 2021.
Since 2006, Lisata Therapeutics insiders reported 43 open-market purchases and 33 sales on Forms 4 and 5, with purchases in 12 different years, most recently 2021.
No open-market sale by an insider of Lisata Therapeutics (LSTA) was filed with the SEC in the last 90 days.
No trade in Lisata Therapeutics (LSTA) was disclosed by a member of Congress in the last 12 months.
Lisata Therapeutics's next results are expected on Mar 10, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$1.21−0.07 (−5.47%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
−41.5% (−$0.86) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $2.07 on Nov 13, 2025 to $1.21 on Nov 13, 2026 (−41.5%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Basking Ridge, Nj.
Last 12 months
−41.5%
Market value
$10.9M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 34K shares sold short (0.4% of shares outstanding), +18.6% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$0
−100.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$12.3M
This quarter −$2.65M, a year earlier −$3.96M
Net debt
—
Debt —, cash $10.4M, at Jun 30, 2026
Net income, last 12 months
−$14.6M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 6, 2025.
Revenue, fiscal 2025
$170K
−83.0% vs the year before
Net income, fiscal 2025
−$16.6M
A loss for the year
Shares outstanding
9.01M
As of Aug 6, 2026
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Lisata Therapeutics reported 43 open-market purchases and 33 sales since 2006; purchases in 12 different years, most recently 2021.
| Year | Bought | Sold |
|---|---|---|
| 2021 | $30K1×1 trade | — |
| 2020 | $100K1×1 trade | — |
| 2017 | — | $70K5×5 trades |
| 2016 | — | $152K9×9 trades |
| 2015 | $145K3×3 trades | $320K1×1 trade |
| 2014 | $338K8×8 trades | $158K4×4 trades |
| 2013 | $50K1×1 trade | $278K5×5 trades |
| 2012 | $25K2×2 trades | $134K5×5 trades |
| 2011 | $672K12×12 trades | — |
| 2010 | $2.54M5×5 trades | $270K2×2 trades |
| 2009 | —2×2 trades | $102K1×1 trade |
| 2008 | —2×2 trades | — |
| 2007 | $54.5M4×4 trades | — |
| 2006 | $30K2×2 trades | $18K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Top officer leaving
“…resigned solely from the office of President, but he retained his position as Chief Executive Officer of the Company.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Last results
Nov 6, 2025
More than 30 days ago
Next results, expected
Mar 10, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
71%
17 of 24 insider purchases since 2011 came within 30 days after a results announcement
From Lisata Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Lisata Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
